Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20.
Marta PillonE CarraroL MussolinV ConterA TondoM AricòR MuraA SalaL VintiS BuffardiP PieraniE S G d'AmoreG BassoPublished in: Pediatric blood & cancer (2017)
Between 2007 and 2013, 13 children diagnosed with primary mediastinal large B-cell lymphoma (PMLBL) were treated according to a modified version of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH-97 protocol based on high-dose methotrexate, anthracyclines, and addition of anti-CD20. Ten patients achieved a continuous complete remission with front-line therapy. The overall 5-year survival was 91.7%, and event-free survival was 83.9%, with only one patient dying of progressive disease. Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.
Keyphrases
- high dose
- free survival
- stem cell transplantation
- low dose
- end stage renal disease
- lymph node
- newly diagnosed
- young adults
- diffuse large b cell lymphoma
- ejection fraction
- chronic kidney disease
- multiple sclerosis
- palliative care
- nk cells
- randomized controlled trial
- oxidative stress
- prognostic factors
- ultrasound guided
- cross sectional
- stem cells
- psychometric properties
- disease activity